Solara Active Pharma Sciences Reports Strong Q1 Performance, Gross Margin Expansion and Cost Control Measures

Solara Active Pharma Sciences Limited has reported a strong performance for the first quarter ended June 30, 2025. The company's revenues have grown by 15% QoQ and 12% YoY, with a gross margin of 54.1%, up by 960 bps YoY. The EBITDA margin stands at 18.0%, up by 639 bps YoY. The company's regulated markets constitute 77% of the total revenues. The Q1’26 PAT is at INR 105 Mn, the highest in the last 12+ quarters. The strong performance is attributed to the company's focus on gross margin expansion and cost control measures.